Standout Papers

The NADPARK study: A randomized phase I trial of nicotinamide riboside supplementation in Parkinson’s disease 2022 2026 2023 2024172
  1. The NADPARK study: A randomized phase I trial of nicotinamide riboside supplementation in Parkinson’s disease (2022)
    Brage Brakedal, Christian Dölle et al. Cell Metabolism

Immediate Impact

4 from Science/Nature 61 standout
Sub-graph 1 of 22

Citing Papers

Targeting mitophagy in neurodegenerative diseases
2025 Standout
Mitochondria in oxidative stress, inflammation and aging: from mechanisms to therapeutic advances
2025 Standout

Works of Frank Riemer being referenced

The NADPARK study: A randomized phase I trial of nicotinamide riboside supplementation in Parkinson’s disease
2022 Standout

Author Peers

Author Last Decade Papers Cites
Frank Riemer 421 92 127 171 40 932
Caroline Guglielmetti 323 52 145 240 28 1.1k
Belinda S.Y. Li 595 77 106 100 17 882
H. Ratiney 543 54 204 145 43 811
Céline Baligand 229 46 98 353 34 788
R. Pokrupa 428 31 77 158 26 1.1k
Yoshimasa Kinoshita 363 34 90 162 51 1.1k
Hiroyasu Nishikawa 473 42 169 279 53 1.1k
Gilbert Hangel 930 184 355 122 50 1.1k
J S Taylor 602 112 329 231 13 1.1k
Navin Bansal 658 130 266 185 45 1.2k

All Works

Loading papers...

Rankless by CCL
2026